This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AZRX AzurRx BioPharma (AZRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About AzurRx BioPharma Stock (NASDAQ:AZRX) 30 days 90 days 365 days Advanced Chart Get AzurRx BioPharma alerts:Sign Up Key Stats Today's Range$0.36▼$0.4050-Day Range$2.40▼$41.0052-Week Range$3.36▼$26.30Volume161,174 shsAverage Volume628,703 shsMarket Capitalization$3.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL. Read More Receive AZRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AZRX Stock News HeadlinesEntero Therapeutics Inc (ENTO)July 30, 2024 | investing.comYS YS Biopharma Co., Ltd.April 11, 2024 | seekingalpha.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 9 at 2:00 AM | Weiss Ratings (Ad)HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship ProgramApril 19, 2023 | finance.yahoo.comFirst Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND FilingJanuary 15, 2023 | marketwatch.comFWBI First Wave BioPharma, Inc.September 16, 2022 | seekingalpha.comFirst Wave BioPharma Inc (FWBI)April 30, 2022 | investing.comFirst Wave BioPharma IncOctober 1, 2021 | reuters.comSee More Headlines AZRX Stock Analysis - Frequently Asked Questions When did AzurRx BioPharma's stock split? AzurRx BioPharma's stock reverse split before market open on Monday, September 13th 2021.The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did AzurRx BioPharma IPO? AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO. What other stocks do shareholders of AzurRx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Company Calendar Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AZRX CIK1604191 Webwww.azurrx.com Phone(649) 699-7855FaxN/AEmployees12Year Founded2014Profitability EPS (Trailing Twelve Months)($11.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-482.96% Return on Assets-258.47% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.76) per share Price / Book-0.51Miscellaneous Outstanding Shares9,326,000Free Float8,645,000Market Cap$3.63 million OptionableNot Optionable Beta1.51 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:AZRX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
